News agency says sweet deal to bring 700 production jobs to the state may be bigger than expected
December 8, 2015 | By Joseph Keenan
State and county incentives used to lure Danish drugmaker Novo Nordisk ($NVO) to build a $1 billion-plus API plant that will create about 700 jobs may cost taxpayers more than $130 million--a number not previously disclosed by public officials.
The Associated Press reported the numbers of the incentive program after reviewing documents it obtained through a public records request. The deal that lured Novo to build its first API plant in the U.S. and locate the facility in Clayton, NC, includes $110 million in tax rebates and infrastructure spending that was not disclosed publicly before, the news agency said.
Novo's U.S. operations president Jesper Høiland
The final incentive number, coupled with other state and local incentives, could reach the $130 million mark or more, because most of the tax breaks were based on the company investing $1.2 billion in the project. Jesper Høiland, president of Novo's U.S. operations, has said the drugmaker plans to invest $1.8 billion.
[Webinar] Moving Along the TMF Maturity Continuum
DATE: DECEMBER 10TH | 2PM ET / 11AM PT
JOIN US FOR THIS WEBINAR TO LEARN HOW THE VEEVA TMF MATURITY MODEL FOR LIFE SCIENCES CAN HELP YOU EVALUATE YOUR TMF OPERATING MODEL AND CREATE A STRATEGY THAT PROPELS YOUR ORGANIZATION ALONG THE TMF CONTINUUM. REGISTER NOW!
Sign up for our FREE newsletter for more news like this sent to your inbox!
It's unclear if the commissioners of Johnston County--the county where the plant is located--knew the bottom-line figure on how much they were giving away in tax revenues when they approved the deal, the AP said. The disclosure of the size of corporate incentive deals falls on the shoulders of government officials and not on the companies, both an attorney who represented the drugmaker in the negotiations and a Novo spokesman told the news service.
In addition to the county tax breaks, Gov. Pat McCrory's administration said it would kick in about $19 million in tax breaks, grants and worker training, and an additional $10.5 million for road and other infrastructure improvements. Part of the money for the roads and infrastructure is offset by money from a nonprofit organization that spends part of North Carolina's cigarette lawsuit settlement money.
The drugmaker has said the new North Carolina plant will manufacture the active ingredients for oral semaglutide, the company's experimental daily oral treatment for Type 2 diabetes. The plant will also manufacture other current and future Novo insulin products.
Novo has been in a building mode in the past few years, adding a $100 million purification pilot plant at its new research facility in Bagsværd, Denmark, and a $100 million insulin plant in Russia.
- read the AP story
Related Articles:
Novo picks Clayton, NC, for its first U.S. API plant
Novo Nordisk looks at building its first U.S. insulin plant
Novo Nordisk beats in Q2 even as U.S. pricing pressures bite
Novo Nordisk's game-changing oral diabetes drug clears Phase II
Novo expects to keep pumping out growth in insulin market
Novo Nordisk betting $3.7B on a blockbuster oral diabetes drug market
Sign Up for FiercePharmaManufacturing!
SHARE
Tweet
Filed Under Novo Nordisk
POPULAR STORIES
MOST READMOST SHARED
Associated Press: Taxpayers' tally to entice Novo Nordisk to NC may top $130M
FDA warning letter blasts Dr. Reddy's for undisclosed testing
Catalent production issues at French plant cause delay in GSK launch
ㅡㅡㅡㅡㅡ
Shares of Novo Nordisk A/S (NYSE:NVO) rose by 4.18% in the past week and 3.84% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 4.1% and the outperformance increases to 4.21% for the last 4 weeks.
Novo Nordisk A/S is up 5.01% in the last 3-month period. Year-to-Date the stock performance stands at 36.87%.The company shares have rallied 24.30% from its 1 Year high price. on Aug 3, 2015, the shares registered one year high at $60.34 and the one year low was seen on Jan 6, 2015. The 50-Day Moving Average price is $54.64 and the 200 Day Moving Average price is recorded at $55.97.
During the last several months other analysts have commented on the company rating. Equity Analysts at the Brokerage Firm, Jyske Bank, upgrades their rating on the shares of Novo Nordisk A/S (NYSE:NVO). Jyske Bank has a Strong Buy rating on the shares. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on October 19, 2015.